GREEN: Trurapi - preferred cost-effective brand (for adults and children's). (Decision date - March 2022, July 2023)
GREEN: Fiasp - on specialist recommendation. New fast acting insulin aspart with a faster onset of action than novorapid, 4 minutes versus 10-20 minutes, for use in adults and children (>1 year). Note: FIASP and Novorapid are not directly interchangeable. (Decision date - June 2017)
GREY: Novorapid - For new patients consider Trurapi as the cost-effective brand. Existing patients on NovoRapid should continue on treatment until the next clinical review takes place, to assess if suitable for switching. (Decision date - March 2022, July 2023)